Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroMed Co. Ltd.

www.viromed.co.kr

Latest From ViroMed Co. Ltd.

Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy

Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.

Research & Development India

Helixmith Facing Engensis Challenges After Disappointing First Phase III Data

Helixmith delays making conclusions on disappointing first top-line data from lead US Phase III study of plasmid DNA therapeutic Engensis, citing unexpected pharmacokinetic results in the placebo and treatment groups. The South Korean biotech vows to improve strategy for upcoming trials, but much may hinge on their success.

Gene Therapy Clinical Trials

Korea Eases Stock Rules To Help Bioventures Stay Listed, Focus On R&D

South Korea continues to ease stock market listing rules to help bioventures and other innovative companies sustain growth and focus on their core R&D activities. 

South Korea Financing

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • ViroMed Ltd.
  • VM BioPharma
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • ViroMed Co. Ltd.
  • Senior Management
  • Yongsoo Kim, PhD, Pres. & CEO
    Sungchul Kim, CFO
    Sunyoung Kim, CSO
  • Contact Info
  • ViroMed Co. Ltd.
    Phone: (82)
    5th Floor, Bldg. 203, Seoul Nat'l Univ.
    599 Gwanak-ro
    Seoul, 151-747
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register